pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

81 catalysts · 17 phase 2 completion · 14 phase 1 completion · 9 patent expiry · 8 phase 2 initiation · 8 phase 1 initiation · 5 drug expiry

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: nsclc×TA: cardiology×TA: infectious-disease×clear all
type
  • phase 2 completion17
  • phase 1 completion14
  • patent expiry9
  • phase 2 initiation8
  • phase 1 initiation8
  • drug expiry5
phase 1 2 completion4
  • phase 3 completion4
  • phase 0 trial completion4
  • constraining patent expiry europe3
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    14
    ›Apr 24, 2026patent expiry90d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026patent expiry90d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026drug expiry90d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry90d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026phase 1 results90d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

    Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

    full page →viral-specific T-cells →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

    Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

    full page →influenza (trivalent, split virion) vaccine →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoShenzhen Salubris Pharmaceuticals Co Ltd — (alisartan calcium + amlodipine besylate + sacubitril) (Phase I Trial Completion)(alisartan calcium + amlodipine besylate + sacubitril)

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →(alisartan calcium + amlodipine besylate + sacubitril) →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

    Therapy area: Infectious Disease. Indication: Dental Abscess

    full page →Gengigel →source: globaldata
    ›Apr 25, 2026phase 2 initiation89d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →dostarlimab →source: globaldata
    ›Apr 26, 2026phase 1 2 completion88d agoMahatma Gandhi Ayurved College Hospital and research centre — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

    Therapy area: Cardiovascular. Indication: Thrombophlebitis

    full page →ayurvedic medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion88d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

    full page →bupivacaine →source: globaldata
    ›Apr 26, 2026phase 2 results88d agoMinistry of Education University and Research, Italy — artichoke (Phase II Trial Results)artichoke

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →artichoke →source: globaldata
    ›Apr 26, 2026phase 3 completion88d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

    Therapy area: Infectious Disease. Indication: Rabies

    full page →rabies vaccine →source: globaldata
    ›Apr 26, 2026phase 3 completion88d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

    Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

    full page →diltiazem →source: globaldata

    Week of Apr 27, 2026

    36
    ›Apr 27, 2026phase 1 initiation87d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

    full page →pembrolizumab →source: globaldata
    ›Apr 27, 2026constraining patent expiry europe
    ← prev
    page 1 of 2
    next →
    87d ago
    Bill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Europe))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026patent expiry87d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026phase 2 completion87d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 initiation87d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 2 initiation87d agoMahatma Gandhi Medical College and Hospital — rosuvastatin (Phase II Trial Initiation)rosuvastatin

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Myocardial Infarction

    full page →rosuvastatin →source: globaldata
    ›Apr 27, 2026phase 2 initiation87d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

    Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

    full page →brincidofovir →source: globaldata
    ›Apr 27, 2026phase 2 initiation87d agoAlfred Health Victoria — amiodarone (Phase II Trial Initiation)amiodarone

    Therapy area: Cardiovascular. Indication: Atrial Fibrillation, Congestive Heart Failure (Heart Failure)

    full page →amiodarone →source: globaldata
    ›Apr 27, 2026phase 3 completion87d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

    Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

    full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata
    ›Apr 27, 2026phase 3 initiation87d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 27, 2026phase iv trial initiation87d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

    Therapy area: Infectious Disease. Indication: Typhoid Fever

    full page →typhoid Vi polysaccharide vaccine →source: globaldata
    ›Apr 28, 2026constraining patent expiry europe86d agoLupin Ltd — (dolutegravir + lamivudine + tenofovir disoproxil fumarate) (Constraining Patent Expiry (Europe))(dolutegravir + lamivudine + tenofovir disoproxil fumarate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(dolutegravir + lamivudine + tenofovir disoproxil fumarate) →source: globaldata
    ›Apr 28, 2026patent expiry86d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry86d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata
    ›Apr 28, 2026patent expiry86d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry86d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026patent expiry86d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry86d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026drug expiry86d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry86d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026pdufa86d agoMerck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)(doravirine + islatravir hydrate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(doravirine + islatravir hydrate) →source: globaldata
    ›Apr 28, 2026phase 1 completion86d agoInternational Bio Service Co Ltd — Bisoprolol fumarate (Phase I Trial Completion)BISOPROLOL FUMARATE

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →BISOPROLOL FUMARATE →source: globaldata
    ›Apr 28, 2026phase 1 completion86d agoGSK plc — bepirovirsen sodium (Phase I Trial Completion)bepirovirsen sodium

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →bepirovirsen sodium →source: globaldata
    ›Apr 28, 2026phase 1 completion86d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 completion86d agoPolfa Tarchomin SA — empagliflozin (Phase I Trial Completion)SYNJARDY

    Therapy area: Cardiovascular, Metabolic Disorders. Indication: Congestive Heart Failure (Heart Failure), Type 2 Diabetes

    full page →SYNJARDY →source: globaldata
    ›Apr 28, 2026phase 2 completion86d agoUniversity of Sao Paulo General Hospital — iloprost (Phase II Trial Completion)iloprost

    Therapy area: Cardiovascular. Indication: Pulmonary Arterial Hypertension

    full page →iloprost →source: globaldata
    ›Apr 28, 2026phase 3 completion86d agoGovernment Stanley Medical College Hospital — tenecteplase (Phase III Trial Completion)tenecteplase

    Therapy area: Genito Urinary System, Infectious Disease. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Unspecified Bacterial Infections

    full page →tenecteplase →source: globaldata
    ›Apr 29, 2026phase 1 completion85d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 1 initiation85d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion85d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation85d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →HH-006 →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe84d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026patent expiry84d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

    Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

    full page →isavuconazonium sulfate →source: globaldata
    $GSK50.90+0.24%
    $GSK50.90+0.24%
    $SNY44.12+0.85%
    $GSK50.90+0.24%
    $GSK50.90+0.24%
    $MRK126.26+1.50%
    $GSK50.90+0.24%
    $GSK50.90+0.24%
    $OCGN1.3000-2.26%
    $CPIX7.7000-1.91%